Leases [Abstract] Remainder of 2019 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three Total future minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Difference between future minimum lease payments and discounted operating lease liabilities Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total operating lease liabilities Operating Lease, Liability Equity [Abstract] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Leased Properties Lessee, Operating Leases [Text Block] Receivables [Abstract] Grant Award Grant Award [Text Block] Grant Award [Text Block] Income Statement [Abstract] Operating expenses Operating Expenses [Abstract] General and administrative General and Administrative Expense Research and development expenses Research and Development Expense License expenses License Fee License Fee Impairment of goodwill Goodwill, Impairment Loss Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Other income Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Deemed dividend from trigger of down round provision feature Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Net loss to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Loss per common share - basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Private Dare Private Dare [Member] Private Dare. Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2015 Stock Incentive Plan Two Thousand And Fifteen Stock Incentive Plan [Member] Two Thousand And Fifteen Stock Incentive Plan [Member] Award Type Award Type [Axis] Equity Award Equity Award [Domain] Employee Stock Option Employee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Canceled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding ending balance (in shares) Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding beginning balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled/forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding ending balance (in usd per share) Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accounting Policies [Abstract] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Measurement Frequency Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Right-of-use assets Operating Lease, Right-of-Use Asset Lease liabilities Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Product and Service Product and Service [Axis] Product and Service Product and Service [Domain] Grant Grant [Member] Health Care Trust Fund Health Care Trust Fund [Axis] Health Care Trust Fund, Name Health Care Trust Fund, Name [Domain] Eunice Kennedy Shriver National Institute of Child Health and Human Development Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Second Phase of Research and Availability of Funds Second Phase Of Research And Availability Of Funds [Member] Second Phase Of Research And Availability Of Funds [Member] Remaining Portion of Research and Availability of Funds Remaining Portion Of Research And Availability Of Funds [Member] Remaining Portion Of Research And Availability Of Funds [Member] Related Party Related Party [Axis] Related Party Related Party [Domain] National Institutes of Health National Institutes Of Health [Member] National Institutes Of Health [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Revenue from grant for notice of award Revenue from Contract with Customer, Excluding Assessed Tax Grants receivable Grants Receivable Cash received from federal grant Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of operating segments Number of Operating Segments Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Organization and Description of the Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Document And Entity Information [Abstract] Document and entity information. Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Current Reporting Status Entity Current Reporting Status Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Square footage of office space Net Rentable Area Term of operating lease Lessee, Operating Lease, Term of Contract Renewal term of operating lease Lessee, Operating Lease, Renewal Term Gross monthly base rent Operating Leases, Rent Expense, Minimum Rentals Percentage of increase in annual base rent, each year Percentage Of Increase In Annual Base Rent Percentage Of Increase In Annual Base Rent Incremental borrowing rate Lessee, Operating Lease, Discount Rate Right of use asset Operating lease liability, short term Operating Lease, Liability, Current Operating lease liability, long term Operating Lease, Liability, Noncurrent Non-cash lease expenses Operating Lease, Cost Cash paid for measurement of operating lease liabilities Operating Lease, Payments Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other receivables Other Receivables, Net, Current Prepaid expenses Prepaid Expense, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Other non-current assets Other Assets, Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable and Accrued Liabilities, Current Accrued expenses Accrued Liabilities, Current Total current liabilities Liabilities, Current Other liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 8) Commitments and Contingencies Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Common stock, $0.0001 par value; 120,000,000 shares authorized; 16,683,411 and 11,422,161 shares issued and outstanding, respectively Common Stock, Value, Issued Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Warrant or Right Class of Warrant or Right [Axis] Class of Warrant or Right Class of Warrant or Right [Domain] Warrants Expiring on December 1, 2021 Warrants Expiring On December One Two Thousand Twenty One [Member] Warrants expiring on december one two thousand twenty one. Warrants Expiring on December 6, 2021 Warrants Expiring On December Six Two Thousand Twenty One [Member] Warrants expiring on december six two thousand twenty one. Warrants Expiring on January 8, 2020 Warrants Expiring On January Eight Two Thousand Twenty [Member] Warrants expiring on january eight two thousand twenty. Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Shares Underlying Outstanding Warrants (in shares) Class of Warrant or Right, Outstanding Exercise Price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Accumulated deficit Cash flow from operations Net Cash Provided by (Used in) Operating Activities Cash and cash equivalents, after payment of transaction expenses Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents After Payment Of Transaction Related Expenses Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents After Payment Of Transaction Related Expenses Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Upon Achievement Of Specified Funding, Product Development, And Regulatory Milestones Upon Achievement Of Specified Funding, Product Development, And Regulatory Milestones [Member] Upon Achievement Of Specified Funding, Product Development, And Regulatory Milestones [Member] Paid In Common Stock Paid In Common Stock [Member] Paid In Common Stock [Member] Upon Achievement Of Specified Sales Of Products Incorporating Intellectual Property Acquired In Merger Upon Achievement Of Specified Sales Of Products Incorporating Intellectual Property Acquired In Merger [Member] Upon Achievement Of Specified Sales Of Products Incorporating Intellectual Property Acquired In Merger [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common stock Common Stock [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock issued (in shares) Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares Cash and cash equivalents Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Contingent consideration Asset Acquisition, Contingent Consideration Asset Acquisition, Contingent Consideration Transaction costs Asset Acquisition, Transaction Costs Asset Acquisition, Transaction Costs Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Project Project [Axis] Project Project [Domain] Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Future Milestone Payments Based on Product Development Future Milestone Payments Based On Product Development [Member] Future Milestone Payments Based On Product Development [Member] Future Milestone Payments Based on Commercialization Future Milestone Payments Based On Commercialization [Member] Future Milestone Payments Based On Commercialization [Member] Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Upon Signing of Development and Option Agreement Upon Signing Of Development And Option Agreement [Member] Upon Signing Of Development And Option Agreement [Member] Upon Completion of Fifty Percent Development Not Later Than Six Months Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] SST Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Orbis Orbis [Member] Orbis [Member] MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Hammock Pharmaceuticals, Inc. Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Type of Arrangement and Non-arrangement Transactions Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions Arrangements and Non-arrangement Transactions [Domain] Licensing Agreements Licensing Agreements [Member] Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Development and Option Agreement Development And Option Agreement [Member] Development And Option Agreement [Member] Juniper Pharmaceuticals, Inc. Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals Juniper Pharmaceuticals [Member] Juniper Pharmaceuticals. ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Clinical And Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Range Range [Axis] Range Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Ovaprene Ovaprene [Member] Ovaprene. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Number of patents issued Number Of Patents Issued Number of patents issued. Number of pending US patent applications Number Of Pending Patents Number Of Pending Patents Number of patents granted Number Of Patents Granted Number Of Patents Granted Number of patent applications in other major markets Number Of Patent Applications Number of patent applications. Minimum spending amounts per year Contractual Obligation Agreement termination period on failing to commercialize in certain designated countries Agreement Termination Period On Failing To Commercialize In Certain Designated Countries Agreement termination period on failing to commercialize in certain designated countries. Milestone payments Research And Development Milestone Payment Research and development milestone payment. Number of designated European countries Number Of Designated Countries Number of designated countries. Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. License agreement, termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Agreement termination on failing to enroll patient within months of production and release Agreement Termination On Failing To Enroll Patient Within Months Of Production And Release Agreement termination on failing to enroll patient within months of production and release. Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Milestone payments, contingent amount Milestone Payments Contingent Amount Milestone payments, contingent amount. License agreement, termination period for discontinued sale of product License Agreement, Termination Period, Discontinued Sale Of Product License Agreement, Termination Period, Discontinued Sale Of Product Secured investment required for license agreement Secured Investment Required For License Agreement Secured investment required for license agreement. License agreement, expiration period License Agreement Expiration Period License agreement expiration period. License agreement, termination period prior to receipt of approval License Agreement Termination Period Prior To Receipt Of Approval License agreement, termination period prior to receipt of approval. License agreement, termination period after receipt of approval License Agreement Termination Period After Receipt Of Approval License agreement, termination period after receipt of approval. License agreement, termination period for applicable license products of applicable countries License Agreement Termination Period For Applicable License Products Of Applicable Countries License agreement, termination period for applicable license products of applicable countries. Prior written notice period for termination of agreement for both parties Notice Period For Termination Of Agreement For Both Parties Notice period for termination of agreement for both parties. Commencement period for stage two upon achievement of stage one Commencement Period For Stage Two Upon Achievement Of Stage One Commencement Period For Stage Two Upon Achievement Of Stage One Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments License agreement, period of continuation from date of first commercial sale of product or process License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process License agreement notice period of termination for breach of payment obligation License Agreement Notice Period Of Termination For Breach Of Payment Obligation License Agreement Notice Period Of Termination For Breach Of Payment Obligation Period of dismissal of bankruptcy petition Period Of Dismissal Of Bankruptcy Petition Period Of Dismissal Of Bankruptcy Petition License agreement notice period of termination for breach of other obligation License Agreement Notice Period Of Termination For Breach Of Other Obligation License Agreement Notice Period Of Termination For Breach Of Other Obligation License agreement, notice period of termination License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination License fee License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Proceeds raised from equity financing Proceeds Raised From Equity Financing Proceeds Raised From Equity Financing Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Accumulated deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning balance Public offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Issuance of common stock Stock Issued During Period, Value, New Issues Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Deemed dividend from trigger of down round provision Net proceeds from issuance of common stock and warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Net proceeds from issuance of common stock and warrants Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued Net loss Foreign currency translation adjustments Ending balance (in shares) Ending balance Going Concern Substantial Doubt about Going Concern [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Restricted Stock Restricted Stock [Member] Stock options outstanding (in shares) Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Options to purchase number of outstanding shares of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Increase in number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Amortized weighted average period Weighted Average Amortization Period Weighted Average Amortization Period Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Subsequent Events Subsequent Events [Text Block] Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Sale of Stock Sale of Stock [Axis] Sale of Stock Sale of Stock [Domain] Underwritten Offering Over-Allotment Option [Member] Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Gross proceeds on sale of shares of common stock Gross Proceeds From Issuance Of Common Stock Gross Proceeds From Issuance Of Common Stock Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Common stock, shares issued and sold (in shares) Issuance costs incurred Payments of Stock Issuance Costs Warrants to purchase common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Public offering price in the Offering (in usd per share) Sale of Stock, Price Per Share Underwriters overallotment option to purchase additional shares of common stock and warrants period Underwriters Option To Purchase Additional Shares Of Common Stock Period Underwriters option to purchase additional shares of common stock period. Underwriters option to purchase additional shares (in shares) Underwriters Option To Purchase Additional Shares Underwriters option to purchase additional shares. Gross proceeds from offering of common stock and warrants Gross Proceeds From Offering Of Common Stock And Warrants Gross Proceeds From Offering Of Common Stock And Warrants Proceeds received in public offering, net of underwriting discounts and offering expenses Sale of Stock, Consideration Received on Transaction Exercise price (in usd per share) Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Amount recorded to additional paid in capital as a result of triggered anti-diluted provisions Warrants exercised (in shares) Number Of Common Stock Warrants Exercised Number of common stock warrants exercised. Business Combinations [Abstract] Schedule Of Business Combination Reverse Merger [Table] Schedule Of Business Combination Reverse Merger [Table] Schedule of business combination reverse merger. Research and Development Expense Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals Inc [Member] Pear Tree Pharmaceuticals, Inc. Business Combination Reverse Merger [Line Items] Business Combination Reverse Merger [Line Items] Business combination reverse merger. Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Unamortized fair value of stock options Business Combination Reverse Merger Unamortized Fair Value Of Stock Options Business combination reverse merger unamortized fair value of stock options. Goodwill impairment charge Transaction costs Business Combination Reverse Merger Stock Purchase Transaction Cost Business combination reverses merger stock purchase transaction cost. Potential cash payments to acquire business Potential Cash Payments To Acquire Business Potential Cash Payments To Acquire Business Consideration amount Business Combination, Consideration Transferred Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Non-cash adjustments reconciling net loss to operating cash flows: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation Share-based Compensation Non-cash lease expenses Non-Cash Lease Expense Non-Cash Lease Expense Acquired in-process research and development Research and Development in Process Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other receivables Increase (Decrease) in Other Receivables Prepaid expenses Increase (Decrease) in Prepaid Expense Other current assets Increase (Decrease) in Other Current Assets Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. Accounts payable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash used in operating activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of Pear Tree and Hydra asset Payments to Acquire Businesses, Gross Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from issuance of common stock and warrants Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Supplemental disclosure of non-cash operating and financing activities: Supplemental Cash Flow Information [Abstract] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Deemed dividend from trigger of down round provision Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Stock options Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Acquisitions Business Combination Disclosure [Text Block]